Table 1.

Clinical variables of the cohort of 134 men undergoing prostate needle biopsy at two institutions in the United States.

Variable	Institution*		All
	Institution 1 BIDMC	Institution 2 UM
All patients	94 (70%)	40 (30%)	134 (100%)
Age (years)	65 [60–70]	61 [54–70]	64 [58–70]
Race+
Caucasian	78 (83%)	35 (88%)	113 (84%)
Non-Caucasian	16 (17%)	5 (12%)	21 (16%)
PSA (ng/mL)	5.0 [4.0–7.0]	5.8 [4.7–10.0]	5.2 [4.0–8.0]
Prostate size by TRUS (cc)	43 [31–57]	43 [30–56]	43 [30–57]
PSA density (ng/mL/cc)	0.12 [0.08–0.19]	0.13 [0.09–0.24]	0.12 [0.08–0.19]
Number of cores taken	12 [12–12]	12 [12–12]	12 [12–12]
Number of cores involved	2 [1–4]	10 [1–12]	2 [1–6]
Percent of cores involved	17 [8–33]	77 [8–100]	17 [8–50]
Prostate cancer diagnosis
No	17 (18)	8 (20)	25 (19)
Yes	77 (82)	32 (80)	109 (81)
Laterality
Bilateral	23 (24)	23 (58)	46 (34)
Left	25 (27)	2 (5)	27 (20)
Right	28 (30)	1 (3)	29 (22)
Unknown	1 (1)	6 (16)	7 (5)
No cancer diagnosis	17 (18)	8 (20)	25 (19)
Gleason score
Gleason ≤ 6	27 (29)	13 (33)	40 (30)
Gleason 7	39 (41)	11 (28)	50 (37)
Gleason ≥ 8	8 (8)	7 (18)	15 (11)
Not applicable or Unknown	20 (21)	9 (23)	29 (22)

^*BIDMC = Beth Israel Deaconess Medical Center; UM = University of Michigan

Abbreviations: PSA = Prostate specific antigen; TRUS = transrectal ultrasound

⁺See Supplemental Table 1 for results on ethnicity by TMPRSS2-ERG fusion status among 100 patients’ prostate cancer-positive biopsy cores